Theres no evidence that they have any sort of substantially lingering effect once you stop taking them, said Patrick ONeil, Ph.D., director of the MUSC Weight Management Center and a professor in the Department of Psychiatry and Behavioral Sciences
The catch: copay cards typically have annual maximums ($5,000-$7,500)
These drugs offer substantial potential health benefits, but the combination of intense demand, new uses, and high prices for these treatments is likely to place tremendous pressure on Medicare spending, Part D plan costs, and premiums for Part D coverage.
Lab tests, prescriptions, additional post-op garments, revision fees, and complication or extended care costs are usually excluded
The exceptions: PT-141 for women uses 1.75 mg subcutaneously (the FDA-approved Vyleesi dose), which differs from the research doses listed for men